Pedro Berraondo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1153799/publications.pdf

Version: 2024-02-01

155 papers	6,294 citations	109137 35 h-index	82410 72 g-index
166 all docs	166 docs citations	166 times ranked	10320 citing authors

#	Article	IF	Citations
1	Cytokines in clinical cancer immunotherapy. British Journal of Cancer, 2019, 120, 6-15.	2.9	720
2	Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nature Medicine, 2019, 25, 470-476.	15.2	459
3	CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. Immunity, 2020, 52, 856-871.e8.	6.6	387
4	Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature, 2019, 569, 428-432.	13.7	313
5	Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). Clinical Cancer Research, 2016, 22, 3924-3936.	3.2	306
6	An RNA toolbox for cancer immunotherapy. Nature Reviews Drug Discovery, 2018, 17, 751-767.	21.5	171
7	Antibodyâ€dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunology and Cell Biology, 2017, 95, 347-355.	1.0	160
8	Targeting NK-cell checkpoints for cancer immunotherapy. Current Opinion in Immunology, 2017, 45, 73-81.	2.4	158
9	Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma. Cancer Research, 2006, 66, 2442-2450.	0.4	129
10	Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. Nature Medicine, 2018, 24, 1899-1909.	15.2	125
11	Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration. Gut, 2017, 66, 1818-1828.	6.1	118
12	IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy. Clinical Cancer Research, 2021, 27, 2383-2393.	3.2	108
13	Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Annals of Oncology, 2018, 29, 1312-1319.	0.6	106
14	Innate immune mediators in cancer: between defense and resistance. Immunological Reviews, 2016, 274, 290-306.	2.8	104
15	Eradication of Large Tumors in Mice by a Tritherapy Targeting the Innate, Adaptive, and Regulatory Components of the Immune System. Cancer Research, 2007, 67, 8847-8855.	0.4	103
16	Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. Cancer Cell, 2019, 36, 613-629.e7.	7.7	99
17	In vitro and in vivo comparative study of chimeric liver-specific promoters. Molecular Therapy, 2003, 7, 375-385.	3.7	97
18	Successful Colon Cancer Eradication after Chemoimmunotherapy Is Associated with Profound Phenotypic Change of Intratumoral Myeloid Cells. Journal of Immunology, 2011, 186, 807-815.	0.4	92

#	Article	IF	Citations
19	Effect of Adeno-Associated Virus Serotype and Genomic Structure on Liver Transduction and Biodistribution in Mice of Both Genders. Human Gene Therapy, 2009, 20, 908-917.	1.4	88
20	Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut, 2011, 60, 341-349.	6.1	87
21	Messenger RNA therapy for rare genetic metabolic diseases. Gut, 2019, 68, 1323-1330.	6.1	76
22	Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. Journal of Hepatology, 2007, 47, 807-815.	1.8	69
23	Revisiting Interleukin-12 as a Cancer Immunotherapy Agent. Clinical Cancer Research, 2018, 24, 2716-2718.	3.2	69
24	TGFÎ² Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies. Molecular Cancer Therapeutics, 2019, 18, 621-631.	1.9	68
25	Peptide inhibitors of transforming growth factorâ€Î² enhance the efficacy of antitumor immunotherapy. International Journal of Cancer, 2009, 125, 2614-2623.	2.3	62
26	Cellular cytotoxicity is a form of immunogenic cell death. , 2020, 8, e000325.		61
27	Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virusâ€“Derived Vectors Fosters Dendritic Cellâ€“Mediated T-cell Cross-Priming. Cancer Research, 2018, 78, 6643-6654.	0.4	60
28	Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. OncoImmunology, 2016, 5, e1062967.	2.1	52
29	Development of a Liver-specific Tet-On Inducible System for AAV Vectors and Its Application in the Treatment of Liver Cancer. Molecular Therapy, 2011, 19, 1245-1253.	3.7	51
30	In vivo depletion of DC impairs the antiâ€tumor effect of agonistic antiâ€CD137 mAb. European Journal of Immunology, 2009, 39, 2424-2436.	1.6	47
31	Myeloid-derived cells are key targets of tumor immunotherapy. OncoImmunology, 2014, 3, e28398.	2.1	47
32	Antitumor Immunotherapeutic and Toxic Properties of an HDL-Conjugated Chimeric IL-15 Fusion Protein. Cancer Research, 2013, 73, 139-149.	0.4	44
33	Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy. Cancer Discovery, 2016, 6, 1312-1314.	7.7	41
34	Gene Therapy: A Pharmacokinetic/Pharmacodynamic Modelling Overview. Pharmaceutical Research, 2010, 27, 1487-1497.	1.7	40
35	Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimineâ€“plasmid complex. Vaccine, 2005, 23, 1384-1392.	1.7	39
36	Intratumoral injection of interferonâ€Î± and systemic delivery of agonist antiâ€CD137 monoclonal antibodies synergize for immunotherapy. International Journal of Cancer, 2011, 128, 105-118.	2.3	39

#	Article	IF	Citations
37	Intravenous Immunoglobulin Promotes Antitumor Responses by Modulating Macrophage Polarization. Journal of Immunology, 2014, 193, 5181-5189.	0.4	39
38	Anchoring interferon alpha to apolipoprotein Aâ€‰reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology, 2011, 53, 1864-1873.	3.6	38
39	Interleukin-15 in Gene Therapy of Cancer. Current Gene Therapy, 2013, 13, 15-30.	0.9	37
40	Novel strategies exploiting interleukin-12 in cancer immunotherapy. , 2022, 239, 108189.		35
41	Treatment of Chronic Viral Hepatitis in Woodchucks by Prolonged Intrahepatic Expression of Interleukin-12. Journal of Virology, 2009, 83, 2663-2674.	1.5	34
42	Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. International Journal of Cancer, 2012, 131, 641-651.	2.3	34
43	Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1326-1334.	1.8	34
44	Protection against Woodchuck Hepatitis Virus (WHV) Infection by Gene Gun Coimmunization with WHV Core and Interleukin-12. Journal of Virology, 2001, 75, 9068-9076.	1.5	32
45	Emerging therapies for acute intermittent porphyria. Expert Reviews in Molecular Medicine, 2016, 18, e17.	1.6	32
46	Differential Interleukinâ€8 thresholds for chemotaxis and netosis in human neutrophils. European Journal of Immunology, 2021, 51, 2274-2280.	1.6	32
47	IFN-Î± gene therapy for woodchuck hepatitis with adeno-associated virus: differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes. Molecular Therapy, 2005, 12, 68-76.	3.7	31
48	Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice. Hepatology, 2006, 44, 623-632.	3.6	31
49	Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.. Journal of Clinical Oncology, 2020, 38, 542-542.	0.8	30
50	Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion. Frontiers in Immunology, 2020, 11, 7.	2.2	29
51	Repurposing the yellow fever vaccine for intratumoral immunotherapy. EMBO Molecular Medicine, 2020, 12, e10375.	3.3	28
52	Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. Journal of Nanobiotechnology, 2021, 19, 102.	4.2	27
53	Intrahepatic Injection of Recombinant Adeno-Associated Virus Serotype 2 Overcomes Gender-Related Differences in Liver Transduction. Human Gene Therapy, 2006, 17, 601-610.	1.4	26
54	Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12. Experimental Hematology, 2002, 30, 195-204.	0.2	25

#	Article	IF	Citations
55	Mathematical Model Approach to Describe Tumour Response in Mice After Vaccine Administration and its Applicability to Immune-Stimulatory Cytokine-Based Strategies. AAPS Journal, 2013, 15, 797-807.	2.2	24
56	Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death. Theranostics, 2020, 10, 4481-4489.	4.6	24
57	Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis. Cancer Gene Therapy, 2010, 17, 20-27.	2.2	23
58	Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SRâ€B1. European Journal of Immunology, 2017, 47, 1108-1118.	1.6	23
59	Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by Î²-Catenin Activation. Cancer Discovery, 2019, 9, 1003-1005.	7.7	23
60	Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. , 2021, 9, e002953.		23
61	CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. Nature Communications, 2021, 12, 7296.	5.8	22
62	Eradication of Liver-Implanted Tumors by Semliki Forest Virus Expressing IL-12 Requires Efficient Long-Term Immune Responses. Journal of Immunology, 2013, 190, 2994-3004.	0.4	21
63	Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. Journal of Hepatology, 2015, 63, 329-336.	1.8	21
64	Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15. OncoImmunology, 2018, 7, e1393597.	2.1	20
65	Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells. OncoImmunology, 2019, 8, e1599636.	2.1	20
66	Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases. Current Gene Therapy, 2009, 9, 62-71.	0.9	19
67	A Semliki Forest virus vector engineered to express IFNÎ± induces efficient elimination of established tumors. Gene Therapy, 2012, 19, 271-278.	2.3	19
68	Modeling Tumor Response after Combined Administration of Different Immune-Stimulatory Agents. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 432-442.	1.3	19
69	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nature Cancer, 2022, 3, 665-680.	5.7	18
70	Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?. Immunotherapy, 2009, 1, 845-853.	1.0	17
71	Cellular immunotherapies for cancer. OncoImmunology, 2017, 6, e1306619.	2.1	17
72	Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice. Cell Death and Disease, 2017, 8, e3083-e3083.	2.7	17

#	Article	IF	Citations
73	A new immune-nanoplatform for promoting adaptive antitumor immune response. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 17, 13-25.	1.7	17
74	Advances in mRNA-based drug discovery in cancer immunotherapy. Expert Opinion on Drug Discovery, 2022, 17, 41-53.	2.5	17
75	Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity. Cell Stress, 2019, 3, 236-239.	1.4	17
76	The Fusion Protein of IFN-Î± and Apolipoprotein A-I Crosses the Bloodâ€“Brain Barrier by a Saturable Transport Mechanism. Journal of Immunology, 2012, 188, 3988-3992.	0.4	16
77	Liver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy. PLoS ONE, 2012, 7, e52370.	1.1	16
78	New trends in antitumor vaccines in melanoma. Annals of Translational Medicine, 2017, 5, 384-384.	0.7	16
79	A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFÎ±, and IL-1Î². Cancer Discovery, 2022, 12, 2140-2157.	7.7	16
80	CD137 Costimulation Counteracts TGFÎ² Inhibition of NK-cell Antitumor Function. Cancer Immunology Research, 2021, 9, 1476-1490.	1.6	15
81	Semi-mechanistic pharmacodynamic modelling of gene expression and silencing processes. European Journal of Pharmaceutical Sciences, 2009, 37, 418-426.	1.9	14
82	Scavenger receptor class B, type I: a promising immunotherapy target. Immunotherapy, 2011, 3, 395-406.	1.0	14
83	Immunological Landscape and Clinical Management of Rectal Cancer. Frontiers in Immunology, 2016, 7, 61.	2.2	14
84	An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria. Human Gene Therapy, 2018, 29, 480-491.	1.4	14
85	Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria. Human Molecular Genetics, 2018, 27, 3688-3696.	1.4	14
86	High Prevalence of Insulin Resistance in Asymptomatic Patients with Acute Intermittent Porphyria and Liver-Targeted Insulin as a Novel Therapeutic Approach. Biomedicines, 2021, 9, 255.	1.4	14
87	Harnessing High Density Lipoproteins to Block Transforming Growth Factor Beta and to Inhibit the Growth of Liver Tumor Metastases. PLoS ONE, 2014, 9, e96799.	1.1	12
88	Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory. , 2021, 9, e001586.		12
89	Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications. Cancers, 2021, 13, 963.	1.7	12
90	Anti-TGFÎ² (Transforming Growth Factor Î²) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, e440-e452.	1.1	12

#	Article	IF	Citations
91	Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms. Cellular and Molecular Immunology, 2020, 17, 576-586.	4.8	12
92	The woodchuck interferon-Î± system: Cloning, family description, and biologic activity. Journal of Medical Virology, 2002, 68, 424-432.	2.5	11
93	Characterization of highâ€capacity adenovirus production by the quantitative realâ€time polymerase chain reaction: a comparative study of different titration methods. Journal of Gene Medicine, 2008, 10, 1092-1101.	1.4	11
94	Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers. Cancers, 2020, 12, 3459.	1.7	11
95	761P Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial. Annals of Oncology, 2020, 31, S589.	0.6	11
96	Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin. OncoImmunology, 2012, 1, 97-99.	2.1	10
97	Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function. OncoImmunology, 2016, 5, e1196309.	2.1	10
98	Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. , 2021, 9, e001587.		10
99	Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model. Oncotarget, 2017, 8, 5247-5255.	0.8	10
100	Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. Oncotarget, 2016, 7, 76891-76901.	0.8	9
101	Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria. Science Translational Medicine, 2022, 14, eabc0700.	5.8	9
102	Chronic exposure to IFNÂ drives medullar lymphopoiesis towards T cell differentiation in mice. Haematologica, 2015, 100, 1014-22.	1.7	8
103	Mechanisms of action for different checkpoint inhibitors. HemaSphere, 2019, 3, 28-30.	1.2	8
104	Interleukin-12 Message in a Bottle. Clinical Cancer Research, 2020, 26, 6080-6082.	3.2	8
105	Overcoming the limitations of cytokines to improve cancer therapy. International Review of Cell and Molecular Biology, 2022, , 107-141.	1.6	7
106	Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells. OncoImmunology, 2012, 1, 118-120.	2.1	6
107	Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells. Cancer Immunology, Immunotherapy, 2015, 64, 717-725.	2.0	6
108	Cancer Immunosurveillance Caught in the Act. Immunity, 2016, 44, 525-526.	6.6	6

#	Article	IF	Citations
109	Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy. Cancer Discovery, 2018, 8, 794-796.	7.7	6
110	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-Î±. Journal of Immunology, 2019, 203, 696-704.	0.4	6
111	Woodchuck dendritic cells generated from peripheral blood mononuclear cells and transduced with recombinant human adenovirus serotype 5 induce antigen-specific cellular immune responses. Journal of Medical Virology, 2007, 79, 522-529.	2.5	5
112	Characterization of woodchuck apolipoprotein Aâ€‘: A new tool for drug delivery and identification of altered isoforms in the woodchuck chronic hepatitis model. Journal of Medical Virology, 2011, 83, 1221-1229.	2.5	5
113	Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives. Expert Opinion on Investigational Drugs, 2013, 22, 827-841.	1.9	5
114	Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and Î±-PD-1. British Journal of Cancer, 2021, 124, 1275-1285.	2.9	5
115	Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases. International Review of Cell and Molecular Biology, 2022, , .	1.6	5
116	Target-Mediated Disposition Model Describing the Dynamics of IL12 and IFNÎ³ after Administration of a Mifepristone-Inducible Adenoviral Vector for IL-12 Expression in Mice. AAPS Journal, 2013, 15, 183-194.	2.2	4
117	Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop. Cancer Research, 2016, 76, 2863-2867.	0.4	4
118	Commentary on Pharmacometrics for Immunotherapy. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 8-10.	1.3	4
119	Rapid isolation and enrichment of mouse NK cells for experimental purposes. Methods in Enzymology, 2020, 631, 257-275.	0.4	4
120	Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice. Frontiers in Pharmacology, 2020, 11, 591293.	1.6	4
121	How can chemoimmunotherapy best be used for the treatment of colon cancer?. Immunotherapy, 2012, 4, 1787-1790.	1.0	3
122	High-density lipoproteins delivering interleukin-15. OncoImmunology, 2013, 2, e23410.	2.1	3
123	Production and use of adeno-associated virus vectors as tools for cancer immunotherapy. Methods in Enzymology, 2020, 635, 185-203.	0.4	3
124	Firefighters for the Wrong Type of Inflammation in Tumors. Cancer Discovery, 2021, 11, 2372-2374.	7.7	3
125	Comprehensive molecular characterization of muscle-invasive bladder cancer (MIBC) treated with durvalumab plus olaparib in the neoadjuvant setting: Neodurvarib trial.. Journal of Clinical Oncology, 2022, 40, 546-546.	0.8	3
126	Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis. OncoImmunology, 2022, 11, .	2.1	3

#	Article	IF	Citations
127	Development of a New Hepatoprotective and Proregenerative Molecule Based on Fibroblast Growth Factor 15/19. Journal of Hepatology, 2016, 64, S184.	1.8	2
128	Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity. Frontiers in Immunology, 2020, 11, 620283.	2.2	2
129	Interim analysis of a phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETHI021).. Journal of Clinical Oncology, 2019, 37, 2613-2613.	0.8	2
130	Kinetic and Dynamic Computational Model-Based Characterization of New Proteins in Mice: Application to Interferon Alpha Linked to Apolipoprotein A-I. PLoS ONE, 2012, 7, e42100.	1.1	2
131	Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. Cancers, 2021, 13, 5049.	1.7	2
132	Production of Recombinant Woodchuck IFNÎ± and Development of Monoclonal Antibodies. Journal of Interferon and Cytokine Research, 2009, 29, 75-82.	0.5	1
133	1069P A multicenter phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumours in adulthood (GETHI021). Annals of Oncology, 2020, 31, S727.	0.6	1
134	Scavenger Receptor Class B Type I is Required for 25â€Hydroxycholecalciferol Cellular Uptake and Signaling in Myeloid Cells. Molecular Nutrition and Food Research, 2020, 64, e1901213.	1.5	1
135	Premortem Tumor Stress in Radioimmunotherapy. Trends in Cancer, 2020, 6, 173-174.	3.8	1
136	Generation and characterization of novel co-stimulatory anti-mouse TNFR2 antibodies. Journal of Immunological Methods, 2021, 499, 113173.	0.6	1
137	Abstract 1698: Cellular cytotoxicity is a form of immunogenic cell death. Cancer Research, 2020, 80, 1698-1698.	0.4	1
138	4-1BB (CD137) in anticancer chimeras. Journal of Experimental Medicine, 2020, 217, .	4.2	1
139	A human IgE bispecific antibody shows potent cytotoxic capacity mediated by monocytes. Journal of Biological Chemistry, 2022, 298, 102153.	1.6	1
140	The woodchuck interferon alpha system: cloning, family description and biologic activity. Journal of Hepatology, 2002, 36, 180-181.	1.8	0
141	350 Gene therapy for chronic hepatitis in the woodchuck model using recombinant adeno-associated virus expressing interferon alpha. Journal of Hepatology, 2004, 40, 106.	1.8	0
142	CS18-5. Bounding interferon alpha to apolipoprotein a-i: A strategy to reduce hematological toxicity while enhancing immunostimulatory properties. Cytokine, 2011, 56, 110.	1.4	0
143	Efficacy of systemic messenger RNA therapy to treat and prevent porphyria attacks in animal models of acute intermittent porphyria. Molecular Genetics and Metabolism, 2018, 123, S70-S71.	0.5	0
144	International Symposium: Trailblazing in Cancer Immunotherapy, October 29â€“31, 2017, Pamplona, Spain. Cancer Immunology, Immunotherapy, 2018, 67, 1809-1813.	2.0	0

#	Article	IF	Citations
145	Abstract 1691: CD137 (4-1BB) costimulation of CD8 T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. , 2021, , .		0
146	Intrahepatic Injection of Recombinant Adeno-Associated Virus Serotype 2 Overcomes Gender-Related Differences in Liver Transduction. Human Gene Therapy, 2006, .	1.4	0
147	Interleukin-15 in Gene Therapy of Cancer. Current Gene Therapy, 2012, 13, 15-30.	0.9	0
148	Abstract 1223: Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.. , 2013, , .		0
149	A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETHI021).. Journal of Clinical Oncology, 2018, 36, TPS3123-TPS3123.	0.8	0
150	Abstract LB-151: Prophylactic TNFÎ± blockade unplugs toxicity and efficacy in immunotherapy anti-PD-1 + anti-CTLA-4 combinations. , 2018, , .		0
151	Abstract 1474: Repurposing the yellow fever vaccine for intratumoral immunotherapy. , 2019, , .		0
152	Abstract 2331: Intratumor adoptive transfer of IL-12 mRNA transiently engineered anti-tumor CD8+ T cells. , 2019, , .		0
153	Abstract 1474: Repurposing the yellow fever vaccine for intratumoral immunotherapy. , 2019, , .		0
154	Abstract 2331: Intratumor adoptive transfer of IL-12 mRNA transiently engineered anti-tumor CD8+ T cells. , 2019, , .		0
155	Revisiting Intracavitary Immunotherapy of Cancer. Clinical Cancer Research, 2022, 28, 1993-1995.	3.2	0